{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T12:18:11Z","timestamp":1778156291708,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shengjuan Hu"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04761-1","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T07:59:25Z","timestamp":1774684765000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Eradication efficacy of empiric bismuth quadruple therapy containing amoxicillin in the first-line treatment of Helicobacter pylori in Ningxia, China"],"prefix":"10.1186","volume":"26","author":[{"given":"Xiaoming","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianmei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Mu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengjuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"4761_CR1","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","volume":"64","author":"K Sugano","year":"2015","unstructured":"Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353\u201367. https:\/\/doi.org\/10.1136\/gutjnl-2015-309252.","journal-title":"Gut"},{"key":"4761_CR2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1523-5378.2007.00518.x","volume":"12","author":"DY Graham","year":"2007","unstructured":"Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007;12:275\u20138. https:\/\/doi.org\/10.1111\/j.1523-5378.2007.00518.x.","journal-title":"Helicobacter"},{"key":"4761_CR3","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s11695-017-2915-z","volume":"28","author":"RM Cerqueira","year":"2018","unstructured":"Cerqueira RM, Correia M, Vilar H, Manso MC. Cumulative Helicobacter pylorieradication rates by adopting first- and second- line regimens proposed by the Maastricht IV consensus in obese patients undergoing gastric bypass surgery. Obes Surg. 2018;28:743\u20137. https:\/\/doi.org\/10.1007\/s11695-017-2915-z.","journal-title":"Obes Surg"},{"key":"4761_CR4","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/00365521.2021.1948606","volume":"56","author":"B Cha","year":"2021","unstructured":"Cha B, Bang BW, Shin JB, Ko EJ, Ko W, Kwon KS, et al. Bismuth containing quadruple therapy versus tailored therapy as first-line treatments for Helicobacter pylori infection in a high clarithromycin resistance area. Scand J Gastroenterol. 2021;56:1017\u201322. https:\/\/doi.org\/10.1080\/00365521.2021.1948606.","journal-title":"Scand J Gastroenterol"},{"key":"4761_CR5","doi-asserted-by":"publisher","first-page":"e12468","DOI":"10.1111\/hel.12468","volume":"23","author":"L Zhuge","year":"2018","unstructured":"Zhuge L, et al. Furazolidone treatment for Helicobacter Pylori infection: A systematic review and meta-analysis. Helicobactervol. 2018;23:e12468.","journal-title":"Helicobactervol"},{"key":"4761_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12876-015-0245-y","volume":"15","author":"N Almeida","year":"2015","unstructured":"Almeida N, Donato MM, Rom\u00e3ozinho JM, Luxo C, Cardoso O, Cipriano MA, et al. Beyond Maastricht IV: are standard empiric triple therapies for Helicobacter pylori still useful in a South-European country? BMC Gastroenterol. 2015;15:23. https:\/\/doi.org\/10.1186\/s12876-015-0245-y.","journal-title":"BMC Gastroenterol"},{"key":"4761_CR7","doi-asserted-by":"publisher","first-page":"e12475","DOI":"10.1111\/hel.12475","volume":"23","author":"WZ Liu","year":"2018","unstructured":"Liu WZ, Xie Y, Lu H, Cheng H, Zeng ZR, Zhou LY, et al. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter. 2018;23:e12475. https:\/\/doi.org\/10.1111\/hel.12475.","journal-title":"Helicobacter"},{"key":"4761_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/hel.12299","volume":"21","author":"Y Hu","year":"2016","unstructured":"Hu Y, Zhang M, Lu B, Dai J. Helicobacter pylori and antibiotic resistance, A continuing and intractable problem. Helicobacter. 2016;21:349\u201363. https:\/\/doi.org\/10.1111\/hel.12299.","journal-title":"Helicobacter"},{"key":"4761_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/hel.12231","volume":"21","author":"A Cosme","year":"2016","unstructured":"Cosme A, Lizasoan J, Montes M, Tamayo E, Alonso H, Mendarte U, et al. Antimicrobial susceptibility-guided therapy versus empirical concomitant therapy for eradication of Helicobacter pylori in a region with high rate of clarithromycin resistance. Helicobacter. 2016;21:29\u201334. https:\/\/doi.org\/10.1111\/hel.12231.","journal-title":"Helicobacter"},{"key":"4761_CR10","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1097\/MEG.0000000000000960","volume":"29","author":"S Costa","year":"2017","unstructured":"Costa S, Soares J-B, Gon\u00e7alves R. Efficacy and tolerability of culture-guided treatment for Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 2017;29:1258\u201363. https:\/\/doi.org\/10.1097\/MEG.0000000000000960.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"4761_CR11","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2169\/internalmedicine.49.3031","volume":"49","author":"Y Wenzhen","year":"2010","unstructured":"Wenzhen Y, Yumin L, Quanlin G, Kehu Y, Lei J, Donghai W, et al. Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials. Intern Med. 2010;49:1103\u20139. https:\/\/doi.org\/10.2169\/internalmedicine.49.3031.","journal-title":"Intern Med"},{"key":"4761_CR12","doi-asserted-by":"publisher","first-page":"5205","DOI":"10.3748\/wjg.v20.i18.5205","volume":"20","author":"G Cammarota","year":"2014","unstructured":"Cammarota G, Ianiro G, Bibb\u00f2 S, Di Rienzo TA, Masucci L, Sanguinetti M, et al. Culture-guided treatment approach for Helicobacter pylori infection: review of the literature. World J Gastroenterol. 2014;20:5205\u201311. https:\/\/doi.org\/10.3748\/wjg.v20.i18.5205.","journal-title":"World J Gastroenterol"},{"key":"4761_CR13","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1111\/apt.15273","volume":"49","author":"Q Chen","year":"2019","unstructured":"Chen Q, Long X, Ji Y, Liang X, Li D, Gao H, et al. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment. Aliment Pharmacol Ther. 2019;49:1385\u201394. https:\/\/doi.org\/10.1111\/apt.15273.","journal-title":"Aliment Pharmacol Ther"},{"key":"4761_CR14","doi-asserted-by":"publisher","first-page":"597","DOI":"10.17235\/reed.2020.7395\/2020","volume":"113","author":"R Bonoso Criado","year":"2021","unstructured":"Bonoso Criado R, P\u00e9rez Citores L, P\u00e9rez Mill\u00e1n AG, Montero Moret\u00f3n \u00c1, Gonz\u00e1lez de Castro E, Cabezudo Molleda L, et al. Prospective comparative study of the treatment of Helicobacter pylori with antibiotic susceptibility testing-guided triple therapy compared to quadruple therapy with bismuth-metronidazole-tetracycline subcitrate. Rev Esp Enferm Dig. 2021;113:597\u2013601. https:\/\/doi.org\/10.17235\/reed.2020.7395\/2020.","journal-title":"Rev Esp Enferm Dig"},{"key":"4761_CR15","doi-asserted-by":"publisher","first-page":"e12561","DOI":"10.1111\/hel.12561","volume":"24","author":"JW Lee","year":"2019","unstructured":"Lee JW, Kim N, Nam RH, Lee SM, Kwon YH, Sohn SD, et al. Favorable outcomes of culture-based Helicobacter pylori eradication therapy in a region with high antimicrobial resistance. Helicobacter. 2019;24:e12561. https:\/\/doi.org\/10.1111\/hel.12561.","journal-title":"Helicobacter"},{"key":"4761_CR16","doi-asserted-by":"publisher","first-page":"175628481987492","DOI":"10.1177\/1756284819874922","volume":"12","author":"L Yu","year":"2019","unstructured":"Yu L, Luo L, Long X, Liang X, Ji Y, Chen Q, et al. Susceptibility-guided therapy for Helicobacter pylori infection treatment failures. Th Adv Gastroenterol. 2019;12:1756284819874922. https:\/\/doi.org\/10.1177\/1756284819874922.","journal-title":"Th Adv Gastroenterol"},{"key":"4761_CR17","first-page":"5027","volume":"11","author":"Z Zhong","year":"2021","unstructured":"Zhong Z, Zhang Z, Wang J, Hu Y, Mi Y, He B, et al. A retrospective study of the antibiotic-resistant phenotypes and genotypes of Helicobacter pylori strains in China. Am J Cancer Res. 2021;11:5027\u201337.","journal-title":"Am J Cancer Res"},{"key":"4761_CR18","doi-asserted-by":"publisher","first-page":"e12960","DOI":"10.1111\/hel.12960","volume":"28","author":"S Hu","year":"2023","unstructured":"Hu S, Zhou Y, Deng Y, Bo Y, Chen X, Yang W, et al. Characteristics of phenotypic antibiotic resistance of Helicobacter pylori and its correlation with genotypic antibiotic resistance: A retrospective study in Ningxia. Helicobacter. 2023;28:e12960. https:\/\/doi.org\/10.1111\/hel.12960.","journal-title":"Helicobacter"},{"key":"4761_CR19","doi-asserted-by":"publisher","first-page":"771876","DOI":"10.3389\/fphar.2022.771876","volume":"13","author":"M Niu","year":"2022","unstructured":"Niu M, Zhou Y, Xie Y, Li X, Tian Y, Yao L, et al. Comparison of the dual therapy of ilaprazole-amoxicillin and the bismuth quadruple therapy of ilaprazole-amoxicillin-furazolidone-bismuthglycyrrhizinate for eradication of Helicobacter pylori. Front Pharmacol. 2022;13:771876. https:\/\/doi.org\/10.3389\/fphar.2022.771876.","journal-title":"Front Pharmacol"},{"key":"4761_CR20","first-page":"304","volume":"58","author":"R Pellicano","year":"2016","unstructured":"Pellicano R, Ribaldone DG, Fagoonee S, Astegiano M, Saracco GM, M\u00e9graud F. A 2016 panorama of Helicobacter pylori infection: key messages for clinicians. Panminerva Med. 2016;58:304\u201317.","journal-title":"Panminerva Med"},{"key":"4761_CR21","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12876-016-0496-2","volume":"16","author":"ATB Abadi","year":"2016","unstructured":"Abadi ATB, Bezmin AT, Kusters JG. Management of Helicobacter pylori infections. BMC Gastroenterol 12 Aug. 2016;16:194. https:\/\/doi.org\/10.1186\/s12876-016-0496-2.","journal-title":"BMC Gastroenterol 12 Aug"},{"key":"4761_CR22","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/ajg.2016.563","volume":"112","author":"WD Chey","year":"2017","unstructured":"Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112:212\u201339. https:\/\/doi.org\/10.1038\/ajg.2016.563.","journal-title":"Am J Gastroenterol"},{"key":"4761_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/QCO.0000000000000396","volume":"30","author":"C Alba","year":"2017","unstructured":"Alba C, Blanco A, Alarc\u00f3n T. Antibiotic resistance in Helicobacter pylori. Curr Opin Infect Dis. 2017;30:489\u201397. https:\/\/doi.org\/10.1097\/QCO.0000000000000396.","journal-title":"Curr Opin Infect Dis"},{"key":"4761_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/1319-3767.91724","volume":"18","author":"DY Graham","year":"2012","unstructured":"Graham DY, Lu H. Furazolidone in Helicobacter pylori therapy: misunderstood and often unfairly maligned drug told in a story of French bread. Saudi J Gastroenterol. 2012;18:1\u20132. https:\/\/doi.org\/10.4103\/1319-3767.91724.","journal-title":"Saudi J Gastroenterol"},{"key":"4761_CR25","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.3748\/wjg.v24.i40.4596","volume":"24","author":"YW Zhang","year":"2018","unstructured":"Zhang YW, Hu WL, Cai Y, Zheng WF, Du Q, Kim JJ, et al. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication. World J Gastroenterol. 2018;24:4596\u2013605. https:\/\/doi.org\/10.3748\/wjg.v24.i40.4596.","journal-title":"World J Gastroenterol"},{"key":"4761_CR26","doi-asserted-by":"publisher","first-page":"e12468","DOI":"10.1111\/hel.12468","volume":"23","author":"L Zhuge","year":"2018","unstructured":"Zhuge L, Wang Y, Wu S, Zhao R-L, Li Z, Xie Y. Furazolidone treatment for Helicobacter Pylori infection: A systematic review and meta-analysis. Helicobacter. 2018;23:e12468. https:\/\/doi.org\/10.1111\/hel.12468.","journal-title":"Helicobacter"},{"key":"4761_CR27","doi-asserted-by":"publisher","first-page":"e7805","DOI":"10.1016\/j.cmi.2017.11.010","volume":"24","author":"DS Liu","year":"2018","unstructured":"Liu DS, Wang YH, Zeng ZR, Zhang ZY, Lu H, Xu JM, et al. Primary antibiotic resistance of Helicobacter pylori in Chinese patients: a multiregion prospective 7-year study. Clin Microbiol Infect. 2018;24:e7805\u20138. https:\/\/doi.org\/10.1016\/j.cmi.2017.11.010.","journal-title":"Clin Microbiol Infect"},{"key":"4761_CR28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/MOG.0000000000000497","volume":"35","author":"SM Smith","year":"2019","unstructured":"Smith SM, O\u2019Morain C, McNamara D. Helicobacter pylori resistance to current therapies. Curr Opin Gastroenterol. 2019;35:6\u201313. https:\/\/doi.org\/10.1097\/MOG.0000000000000497.","journal-title":"Curr Opin Gastroenterol"},{"key":"4761_CR29","doi-asserted-by":"publisher","first-page":"e12585","DOI":"10.1111\/hel.12585","volume":"24","author":"SW KwonYH, Jeon","year":"2019","unstructured":"KwonYH, Jeon SW, Nam SY, Lee HS, Park JH. Efficacy of tailored therapy for Helicobacter pylori eradication based on clarithromycin resistance and survey of previous antibiotic exposure: A single-center prospective pilot study. Helicobacter. 2019;24:e12585. https:\/\/doi.org\/10.1111\/hel.12585.","journal-title":"Helicobacter"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04761-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04761-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04761-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T12:02:28Z","timestamp":1778155348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04761-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4761"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04761-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6363050\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"2 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants signed an informed consent form before participating in the study. The study protocol was approved by the Ethics Committee of Ningxia Hui Autonomous Region People\u2019s Hospital (2022LW006), and in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"277"}}